Cochrane · systematic review · CD005582
Corticosteroids for preventing postherpetic neuralgia
Jiang, X, Li, Y, Chen, N, et al. · Cochrane Database of Systematic Reviews · 2023 · Cochrane Library
SoF tableOnly the outcomes this review put in its Summary of Findings table are listed (the Cochrane Handbook caps them at about seven per comparison). Its other analyses are not shown here.
Questions
3
current version
GRADE rated
3
No studies
0
Included studies
NR
No studies 0 · 0%Ungraded 0 · 0%Very low 2 · 66.7%Low 1 · 33.3%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
Questions and results
Current version onlyCorticosteroids for acute herpes zoster to prevent postherpetic neuralgia
Population: people with acute herpes zoster (within 7 days of onset of rash)
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Presence of PHN 6 months after the onset of acute herpetic rashClinical manifestation | RR 0.95 [0.45, 1.99] | 2 studies · 114 participants | Very low Downgraded: risk of bias, imprecision |
Serious adverse eventsClinical manifestation and laboratory examination | RR 1.65 [0.51, 5.29] | 5 studies · 755 participants | Very low Downgraded: risk of bias, imprecision |
Non‐serious adverse eventsClinical manifestation and laboratory examination | RR 1.3 [0.9, 1.87] | 5 studies · 755 participants | Low Downgraded: risk of bias, imprecision |
Corticosteroids for acute herpes zoster to prevent postherpetic neuralgia
Population: patients with acute herpes zoster to prevent postherpetic neuralgia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Presence of PHN six months after the onset of the acute herpetic rash Clinical manifestation | RR 0.95 [0.45, 1.99] | 2 studies · 114 participants | Moderate Downgraded: risk of bias |
Serious adverse events Clinical manifestation and laboratory examination | RR 1.65 [0.38, 5.29] | 5 studies · 755 participants | Moderate Downgraded: risk of bias |
Non‐serious adverse events Clinical manifestation and laboratory examination | RR 1.3 [0.9, 1.87] | 5 studies · 755 participants | Moderate Downgraded: risk of bias |
Corticosteroids for acute herpes zoster to prevent postherpetic neuralgia
Population: patients with acute herpes zoster to prevent postherpetic neuralgia
| Outcome | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Presence of PHN six months after the onset of the acute herpetic rash clinical manifestation | RR 0.95 [0.45, 1.99] | 2 studies · 114 participants | Moderate Downgraded: risk of bias |
Serious adverse events clinical manifestation and laboratory examination | RR 1.65 [0.38, 5.29] | 5 studies · 755 participants | Moderate Downgraded: risk of bias |
Non‐serious adverse events clinical manifestation and laboratory examination | RR 1.3 [0.9, 1.87] | 5 studies · 755 participants | Moderate Downgraded: risk of bias |